Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
Carregando...
Citações na Scopus
63
Tipo de produção
article
Data de publicação
2017
Editora
ELSEVIER IRELAND LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
KNEBEL, Franciele H.
BETTONI, Fabiana
SHIMADA, Andrea K.
CRUZ, Manoel
REIS, Luiz Fernando L.
KATZ, Artur
CAMARGO, Anamaria A.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
LUNG CANCER, v.108, p.238-241, 2017
Resumo
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. However, acquired resistance to osimertinib is also observed and the molecular mechanisms of resistance are not yet fully understood. Monitoring and managing NSCLC patients who progressed on osimertinib is, therefore, emerging as an important clinical challenge. Sequential liquid biopsies were used to monitor a patient with EGFR-exon19del positive NSCLC, who received erlotinib and progressed through the acquisition of the EGFR-T790M mutation. Erlotinib was discontinued and osimertinib was initiated. Blood samples were collected at erlotinib progression and during osimertinib treatment for the detection of the activating (EGFR-exon19del) and resistance mutations (EGFR-T790M, EGFR-C797S, BRAF-V600E, METamp and ERBB2amp) in the plasma DNA using digital droplet PCR. Plasma levels of the activating EGFR-exon19del accurately paralleled the clinical and radiological progression of disease and allowed early detection of AR to osimertinib. Resistance to osimertinib coincided with the emergence of a small tumor cell subpopulation carrying the known EGFR-C797S resistance mutation and an additional subpopulation carrying amplified copies of EGFR-exon19del. Given the existence of multiple AR mechanisms, quantification of the original EGFR activation mutation, instead of the resistance mutations, can be efficiently used to monitor response to osimertinib, allowing early detection of AR. Absolute quantification of both activation and resistance mutations can provide important information on tumor clonal evolution upon progression to osimertinib. Selective amplification of the EGFR-exon19del allele may represent a novel resistance mechanism to osimertinib.
Palavras-chave
Osimertinib, EGFR, Lung cancer, Acquired resistance, Liquid biopsy
Referências
- Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104
- Chia PL, 2016, LUNG CANCER, V98, P29, DOI 10.1016/j.lungcan.2016.05.003
- Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337
- Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817
- Jiang T, 2015, LUNG CANCER, V90, P128, DOI 10.1016/j.lungcan.2015.09.013
- Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688
- Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674
- Nukaga S., 2017, CANC RES IN PRESS
- Tan DSW, 2016, J THORAC ONCOL, V11, P946, DOI 10.1016/j.jtho.2016.05.008
- Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854